非小细胞肺癌患者EGFR突变与PET/CT<sup>18</sup>F-FDG摄取之间的相关性-东南大学学报医学版

非小细胞肺癌患者EGFR突变与PET/CT¹⁸F-FDG摄取之间的相关性

单位：1. 东南大学医学院, 江苏南京 210009;
2. 东南大学附属中大医院放射科与核医学科, 江苏南京 210009;
3. 南京医科大学, 江苏南京 210029

分类号：R734.2

出版年·卷·期（页码）：2017·36·第五期（760-763）

摘要：

目的：研究非小细胞肺癌组织表皮生长因子受体（EGFR）突变情况与肿瘤组织¹⁸F-脱氧葡萄糖（¹⁸F-FDG）摄取的关系。方法：回顾性分析经病理证实的126例非小细胞肺癌患者的临床资料，于治疗前行¹⁸F-FDG PET/CT检查及EGFR基因突变检测，分析FDG最大标准摄取值（SUV_max）与EGFR突变之间的关系。结果：本组病例中有51例患者（40.5%）19及21外显子突变，突变型患者原发灶的SUV_max低于野生型患者（6±4 vs 11±6，P＝0.014），用SUV_max预测EGFR突变时，受试者工作特征曲线（ROC曲线）下面积是0.769，P=0.001；当SUV_max取界值8.15时，约登指数最大为0.455。结论：非小细胞肺癌原发灶¹⁸F-FDG摄取与EGFR突变存在相关性，EGFR突变更易发生在低SUV_max患者。

Objective:To evaluate the relationship between the presence of epidermal growth factor receptor (EGFR) mutations and 18-fluoro-2-deoxyglucose(¹⁸F-FDG) uptake of primary tumor in patients with non-small cell lung cancer (NSCLC). Methods:Totally 126 patients with NSCLC diagnosed by pathology were collected, who underwent PET/CT examinations and EGFR mutation tests before any anti-tumor therapies, the relationship between the maximum standard uptake value (SUVmax) and the EGFR mutation was analyzed. Results:EGFR mutations within exons 19 and 21 were detected in 51 NSCLC patients (40.5%), the SUV_max was significantly lower in EGFR mutant-type than wild-type (6±4 vs 11±6, P=0.014). For the prediction of EGFR mutations by SUV_max, the area under the receiver operating characteristic curve(AUC) was 0.769, P=0.001. When the cut off value was 8.15, the Youden index reached the maximum value 0.455. Conclusion:¹⁸F-FDG uptake is associated with the presence of EGFR mutation, patients with lower SUV_max are more likely to harbor EGFR mutations.

参考文献：

[1] THUNNISSEN E,van der OORD K,den BAKKER M.Prognostic and predictive biomarkers in lung cancer.A review[J].Virchows Arch,2014,464(3):347-358.
[2] LEE C K,BROWN C,GRALLA R J,et al.Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival:a meta-analysis[J].J Natl Cancer Inst,2013,105(9):595-605.
[3] 李龙,张红,唐发兵,等.肺癌组织表皮生长因子受体与RAS/MARK信号通路活化蛋白ERK1/2表达的相关性及其临床意义[J].东南大学学报:医学版,2013,32(2):218-221.
[4] SHIGEMATSU H,LIN L,TAKAHASHI T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J].J Natl Cancer Inst,2005,97(5):339-346.
[5] NA I I,BYUN B H,KANG H J,et al.18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer[J].Clin Cancer Res,2008,14(7):2036-2041.
[6] SORDELLA R,BELL D W,HABER D A,et al.Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J].Science,2004,305(5687):1163-1167.
[7] PUTORA P M,FRUH M,MULLER J.FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma[J].Respirology,2013,18(4):734-735.
[8] CHUNG H W,LEE K Y,KIM H J,et al.FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma[J].J Cancer Res Clin Oncol,2014,140(1):89-98.
[9] MAK R H,DIGUMARTHY S R,MUZIKANSKY A,et al.Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer[J].Oncologist,2011,16(3):319-326.
[10] NA I I,BYUN B H,KIM K M,et al.18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer:a single-institution retrospective analysis[J].Lung Cancer,2010,67(1):76-80.
[11] 叶媛媛,周丽娟,郏潜新,等.非小细胞肺癌PET/CT表现与病理特征之间的相关性分析[J].医学影像学杂志,2016(3):442-445.
[12] 张炜,郭万华.^99mTc-MDP全身骨扫描和血清CEA、NSE、CYFR21-1、CA125测定对小细胞肺癌骨转移的临床评价[J].东南大学学报:医学版,2015,34(6):881-885.
[13] 牟坤,杨福利,亓久德.序贯性用药对表皮生长因子受体突变阳性的晚期非小细胞型肺癌患者远期预后的影响[J].现代医学,2016,44(4):516-519.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录